Biotech companies either avoid paid media entirely — leaving market share to competitors — or run generic campaigns that waste budget on unqualified audiences. Performance marketing for pharma requires deep regulatory knowledge, precise audience targeting, and creative that converts within compliance boundaries.
The Problem
Generic digital agencies don't understand pharma compliance
Your agency runs great B2C campaigns. But they've never navigated fair balance requirements, ISI placement on digital ads, or the distinction between branded and unbranded pharma campaigns. Every ad that violates FDA guidelines is a warning letter waiting to happen. And every campaign that gets killed in medical-legal review because the agency didn't understand the rules is wasted development time and budget.
Physician targeting requires specialized data and channel strategy
Reaching physicians through paid media isn't like targeting consumers. NPI-based targeting, medical journal placements, and conference-adjacent campaigns require specialized data partnerships and platform knowledge. Most performance marketing teams have never built a physician targeting strategy, so they default to broad LinkedIn campaigns that reach office managers instead of prescribers.
Patient awareness campaigns face unique measurement challenges
You can't track patient conversions the way you track SaaS signups. HIPAA constraints limit pixel-based tracking. Prescription data has attribution lag. The result is that most biotech companies either can't measure paid media ROI — leading to budget cuts — or use vanity metrics that overstate actual impact. Without proper measurement infrastructure built for pharma constraints, performance marketing investment stays perpetually undervalued.
How We Help
Our initial assessment evaluates your paid media opportunity across three audience segments: physicians (branded and unbranded HCP campaigns), patients (disease awareness and branded patient campaigns), and payers (market access and value messaging). We audit current spend, review compliance processes, and identify the targeting and measurement gaps that are limiting performance.
Strategy development builds channel-specific plans for each audience with compliance built in from the start — not bolted on during review. Physician campaigns use NPI-targeted placements, medical journal networks, and conference-adjacent digital strategies. Patient campaigns segment by disease awareness stage and use compliant creative that drives action within ISI and fair balance requirements. Payer-directed campaigns focus on health economics messaging through targeted digital channels.
Execution manages the full campaign lifecycle — creative development, medical-legal review coordination, media buying, and optimization. Our team understands pharma ad review processes, so creative concepts are designed to survive MLR from the beginning. This eliminates the cycle of create-review-reject-recreate that makes most pharma marketing teams despise paid media. We manage campaign optimization within compliance boundaries, adjusting targeting and creative based on performance data.
Measurement builds pharma-appropriate attribution models that account for HIPAA constraints and prescription data lag. We connect paid media activity to downstream commercial metrics — physician engagement depth, patient enrollment inquiries, prescription lift in targeted geographies — rather than relying on click-through rates that tell you nothing about commercial impact.
What we deliver
- Compliant campaign architecture — branded and unbranded strategies with MLR-ready creative frameworks
- Physician targeting strategy — NPI-based campaigns across medical and professional channels
- Patient awareness programs — disease education and branded campaigns within regulatory guardrails
- Pharma attribution model — measurement framework built for HIPAA constraints and prescription data lag
Performance marketing in pharma isn't harder because of compliance — it's harder because most agencies don't know how to be creative within compliance. The companies winning market share through paid media aren't bending rules. They're building campaigns that are compliant by design, not compliant by accident.
Our Methodology
Our performance marketing methodology for biotech starts with compliance infrastructure, not campaign creative. Phase one audits your medical-legal review process, identifies bottlenecks, and establishes creative frameworks that pass MLR consistently. We also set up pharma-appropriate measurement infrastructure — HIPAA-compliant tracking, prescription data partnerships, and attribution models that account for the lag between paid media exposure and prescribing behavior.
Phase two launches initial campaigns across priority audience segments with controlled budgets. We test creative concepts, targeting approaches, and channel strategies to establish performance baselines before scaling spend. Each campaign follows a compliance-first creative process: brief development, MLR pre-alignment, creative production, formal review, and launch.
Phase three scales proven campaigns and optimizes continuously. Budget allocation shifts based on performance data across physician, patient, and payer segments. Quarterly strategy reviews reassess channel mix, creative refresh needs, and measurement model accuracy.
How We Work
Performance marketing engagements for biotech typically run 6-12 months with the first 45 days focused on compliance infrastructure, measurement setup, and initial campaign development. We audit your current paid media activities, establish compliant creative workflows, and build the attribution models needed to measure pharma-specific outcomes.
Months 2-3 launch initial campaigns with controlled budgets across priority audience segments. We test messaging, targeting, and channel strategies to establish baselines. Creative goes through your MLR process with our team managing revisions and approvals — our familiarity with pharma review processes typically reduces review cycles significantly.
Months 4-12 scale proven campaigns, launch new audience segments, and continuously optimize. We manage monthly budget allocation, creative refreshes, and performance reporting. Weekly performance reviews track campaign-level metrics. Monthly strategy sessions connect paid media performance to commercial outcomes.
Your team provides clinical accuracy review and MLR coordination. We handle strategy, creative development, media buying, and optimization. Most clients allocate 1-2 hours per week of internal time to campaign oversight and approvals.
- Physician engagement — HCP reach and engagement through compliant targeted campaigns
- Patient awareness — disease education and branded campaign performance within regulatory guidelines
- Marketing efficiency — reduced cost per qualified interaction through pharma-optimized targeting
If your biotech & pharma company needs performance marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does performance marketing cost for biotech companies?
Management fees typically range from $15K-$40K per month plus media spend. Total investment depends on your audience segments (HCP only vs. HCP + patient + payer), competitive intensity, and geographic scope. Media budgets for initial testing start at $20K-$50K per month and scale based on performance. Compared to the cost of a field team expansion or additional sales reps, digital performance marketing often delivers better cost per physician engagement.
How do you handle FDA compliance in paid media campaigns?
Compliance is built into our creative process from the start, not reviewed at the end. We design creative concepts within known regulatory parameters — fair balance requirements, ISI placement rules, branded vs. unbranded distinctions. Our creative briefs include compliance considerations so that concepts entering MLR are already aligned with regulatory expectations. This approach typically reduces review cycles and rejection rates compared to agencies learning pharma rules on the job.
How long before we see results from pharma performance marketing?
Initial engagement metrics (physician reach, click-through rates, patient awareness) appear within 30-60 days. Commercial impact metrics — prescription lift, physician engagement quality, patient enrollment inquiries — require 3-6 months due to the natural lag between awareness and prescribing behavior. We establish leading indicators that predict commercial impact while waiting for downstream conversion data.
What makes Winston Francois different from pharma digital agencies?
Most pharma agencies treat compliance as an obstacle that limits creativity. We treat it as a design constraint that shapes creative strategy. Our team combines performance marketing expertise with pharma regulatory knowledge, meaning campaigns are built to perform within compliance boundaries from the start. We also connect paid media performance to commercial outcomes, not just digital metrics.
How do you measure performance marketing ROI with HIPAA constraints?
We build attribution models designed for pharma's measurement limitations. This includes HIPAA-compliant tracking infrastructure, prescription data partnerships for geographic lift analysis, physician engagement scoring models, and patient enrollment correlation analysis. We never rely on pixel-based conversion tracking for clinical outcomes — instead building proxy metrics validated against real prescribing data.
What type of biotech company should invest in performance marketing?
Commercial-stage companies with approved products benefit most immediately — paid media directly supports physician awareness and patient enrollment. Late-stage clinical companies benefit from unbranded disease awareness campaigns that build market readiness before launch. Early-stage companies should focus on corporate brand and investor marketing, not patient or physician campaigns. The first step is a paid media audit to assess your opportunity and compliance readiness.
